Proton beam therapy for metastatic liver tumors

Radiother Oncol. 2015 Nov;117(2):322-7. doi: 10.1016/j.radonc.2015.09.011. Epub 2015 Sep 15.

Abstract

Purpose: The purpose of this study was to investigate the safety and efficacy of proton beam therapy (PBT) for the treatment of metastatic liver tumors.

Material and methods: A total of 140 patients with liver metastasis who received PBT were retrospectively investigated. The main primary tumor sites were the colorectum (60) and the pancreas (19).

Results: One hundred thirty-three patients (95%) completed treatment. Two patients experienced late adverse effects (rib fracture and cholangitis). The 5-year overall survival (OS) rate was 24%. In the 85 patients with lesions confined to the liver, the 5-year OS rate of was 28%, and in the 55 patients with lesions both inside and outside the liver, it was 16% (P=0.007). Among the patients with lesions confined to the liver, the 5-year OS rate of the 62 patients who received curative treatment was 30%, and that of the 23 patients who received palliative treatment, 23% (P=0.016). Multivariate analysis showed that the treatment strategy (curative and palliative) alone was associated with the OS rate (P=0.02).

Conclusion: PBT is a potentially safe and effective treatment for metastatic liver tumors.

Keywords: Metastatic liver tumor; Proton beam therapy; Survival rate.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Colorectal Neoplasms / pathology*
  • Female
  • Humans
  • Liver Neoplasms / radiotherapy*
  • Liver Neoplasms / secondary*
  • Male
  • Middle Aged
  • Pancreatic Neoplasms / pathology*
  • Proton Therapy / methods*
  • Retrospective Studies
  • Survival Rate
  • Treatment Outcome
  • Young Adult